| Sponsor |
Protocol Code |
Trial Name |
Principal Investigator |
Phase |
Therapeutic Area |
Diseases and Conditions |
| GSK |
222291 |
A Dose-Finding, Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of GSK4532990 in Adults with Alcohol-related Liver Disease (ALD) - STARLIGHT |
SÜLEYMAN CİHAN YURDAYDIN (Prof.Dr.) |
Phase 2b |
Gastroenterology and Hepatology |
Liver Disease |
| 89BIO Inc. |
BIO89-100-132 |
A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects with Compensated Cirrhosis due to Metabolic Dysfunction-Associated Steatohepatitis (MASH) |
MÜJDAT ZEYBEL (Prof.Dr.) |
Phase 3 |
Gastroenterology and Hepatology |
Liver Disease |
| Boehringer Ingelheim |
1404-0044 |
A Randomised, Double-Blind, Placebo-Controlled, Multicentre, Phase III Trial Evaluating Long-Term Efficacy and Safety of Survodutide Weekly Injections in Adult Participants with Non-cirrhotic Non-alcoholic Steatohepatitis/Metabolic Associated Steatohepatitis (NASH/MASH) and (F2)-(F3) Stage of Liver Fibrosis |
MÜJDAT ZEYBEL (Prof.Dr.) |
Phase 3 |
Gastroenterology and Hepatology |
Liver Disease |
| Boehringer Ingelheim |
1404-0064 |
A Phase III Double-Blind, Randomised, Placebo-Controlled Trial to Evaluate Liver-Related Clinical Outcomes and Safety of Once Weekly Injected Survodutide in Participants with Compensated Non-alcoholic Steatohepatitis/Metabolic Dysfunction Associated Steatohepatitis (NASH/MASH) Cirrhosis |
MÜJDAT ZEYBEL (Prof.Dr.) |
Phase 3 |
Gastroenterology and Hepatology |
Liver Disease |
| 89BIO Inc. |
BIO89-100-131 |
A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis |
MÜJDAT ZEYBEL (Prof.Dr.) |
Phase 3 |
Gastroenterology and Hepatology |
Liver Disease |
| Bluejay Therapeutics, Inc. |
BJT-778-301 |
A Global, Randomized, Open-label, Multicenter, Phase 2b/3 Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-1) |
SÜLEYMAN CİHAN YURDAYDIN (Prof.Dr.) |
Phase 2b/3 |
Gastroenterology and Hepatology |
Chronic Hepatitis D (HDV) Infection |
| Johnson and Johnson |
77242113CRD3001 |
A Phase 2b/3 Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Protocol to Evaluate the Efficacy and Safety of Icotrikina in Participants with Moderately to Severely Active Crohn's Disease |
ALPER YURCİ (Prof.Dr.) |
Phase 2 |
Gastroenterology and Hepatology |
Inflammatory Bowel Disease |
| Gilead Sciences, Inc. |
GS-US-567-6968 |
Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of GS-4321 in Healthy Participants and Participants with Chronic Hepatitis Delta |
SÜLEYMAN CİHAN YURDAYDIN (Prof.Dr.) |
Phase 2 |
Gastroenterology and Hepatology |
Chronic Hepatitis D (HDV) Infection |